LIAISON® SARS-CoV-2 SOLUTIONS

The testing solutions for the detection of antibodies to SARS-CoV-2

 DiaSorin provides diagnostic laboratories with 2 antibodies detection kits to SARS-CoV-2:

  • LIAISON® SARS-CoV-2 IgM
  • LIAISON® SARS-CoV-2 S1/S2 IgG

The testing solutions are based on:

  • Two results from a single sample to determine both antibodies results
  • The selection of Spike protein antigens for both assays, recognized to be the most likely target of future COVID-19 vaccines and for IgG neutralizing antibodies
  • High sensitivity and specificity to ensure accurate results along the infection window

 Download the FAQs

LIAISON® SARS-CoV-2 S1/S2 IgG
A quantitative assay with correlation to neutralizing antibodies

 

 

 

  • A quantitative assay for the detection of IgG antibodies against S1/S2 antigens of SARS-CoV-2
  • A fully automated solution with up to 170 results/hour on LIAISON® XL
  • Detection of Neutralizing antibodies: 94.4% positive agreement to Plaque Reduction Neutralization Test (PRNT90)
  • High sensitivity and specificity to assure accurate results
LIAISON® SARS-CoV-2 IgM
A new qualitative assay for the detection of IgM antibodies to SARS-CoV-2

 

 

 

  • A qualitative assay for the detection of IgM antibodies against S1-RBD antigens of SARS-CoV-2
  • A fully automated solution on LIAISON® XL
  • High sensitivity and specificity to ensure accurate results
Combined IgG and IgM testing
The combined testing solutions for the detection of antibodies to SARS-CoV-2

 

 

 

  • Combined detection of IgM and IgG can be used to assess the immune status of patients exposed to and infected by SARS-CoV-2.
  • The use of IgG and IgM in combination can aid to shorten the diagnostic window improving the detection of seroconversion up to day 15 from PCR positivity